

# Dapagliflozin for treating chronic kidney disease

Information for the public

Published: 9 March 2022

[www.nice.org.uk](http://www.nice.org.uk)

Dapagliflozin (Forxiga) is available on the NHS as a possible treatment for chronic kidney disease in adults if:

- it is given alongside standard care, which includes the highest licensed dose of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers that you can tolerate, if you can have them
- you have an estimated glomerular filtration rate of 25 ml/min/1.73 m<sup>2</sup> to 75 ml/min/1.73 m<sup>2</sup> at the start of treatment and you have:
  - type 2 diabetes or
  - a urine albumin-to-creatinine ratio of 22.6 mg/mmol or more.

If you are not eligible for dapagliflozin but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

This organisation can give you advice and support: [Kidney Care UK](#), 01420 541424.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4471-2